title: Incidence and clinical impact of fluoroquinolone-resistant Escherichia coli in the faecal flora of cancer patients treated with high dose chemotherapy and ciprofloxacin prophylaxis.
abstract: This study evaluated the susceptibility of Escherichia coli to quinolones in 72 stool samples collected from 31 patients with solid tumours who had undergone high dose chemotherapy (HDC) and peripheral blood stem-cell (PBSC) rescue with ciprofloxacin prophylaxis. Samples were obtained at admission, after completing prophylaxis and three months later. All E. coli strains isolated from baseline samples were susceptible to quinolones. Fluoroquinolone-resistant E. coli strains were isolated in 10 (32%) patients in the second sample. In eight of these patients isolates were susceptible 3 months later. No patient developed infection due to fluorquinolone-resistant E. coli. No differences were observed in outcome between patients with susceptible and resistant flora.
authors.affiliation: Division of Microbiology, Hospital Universitario 12 de Octubre, Madrid, Spain.
authors.forename: S
authors.initials: S
authors.lastname: Perea
authors.forename: M
authors.initials: M
authors.lastname: Hidalgo
authors.forename: A
authors.initials: A
authors.lastname: Arcediano
authors.forename: M J
authors.initials: MJ
authors.lastname: Ramos
authors.forename: C
authors.initials: C
authors.lastname: Gomez
authors.forename: J
authors.initials: J
authors.lastname: Hornedo
authors.forename: C
authors.initials: C
authors.lastname: Lumbreras
authors.forename: D
authors.initials: D
authors.lastname: Folgueira
authors.forename: H
authors.initials: H
authors.lastname: Cortes-Funes
authors.forename: A
authors.initials: A
authors.lastname: Rodriguez-Noriega
mesh_terms: D000328:Adult; D000890:Anti-Infective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D019072:Antibiotic Prophylaxis; D000970:Antineoplastic Agents / Q000627:therapeutic use; D016470:Bacteremia / Q000382:microbiology; D002939:Ciprofloxacin / Q000494:pharmacology / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004352:Drug Resistance, Microbial; D004926:Escherichia coli / Q000187:drug effects* / Q000302:isolation & purification; D005243:Feces / Q000382:microbiology*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy / Q000382:microbiology* / Q000628:therapy
chemical_list: D000890:Anti-Infective Agents; D000970:Antineoplastic Agents; D002939:Ciprofloxacin